David Jagielski (Eli Lilly): It may look as though Eli Lilly's stock has peaked given its recent slide, but there's still a lot more room for it to run higher. Vertex Pharmaceuticals (NASDAQ ...
Truist Financial’s price objective would suggest a potential ... and hedge funds own 90.96% of the company’s stock. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages ...
JPMorgan lowered the firm’s price target on Vertex Pharmaceuticals (VRTX ... s “underwhelming” Phase 2 results and views the stock as “likely to work higher in 2025 with two key launches ...
Jefferies analyst Michael Yee has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...